LY2439821, a humanized anti-interleukin-17 monoclonal antibody, in the treatment of patients with rheumatoid arthritis: A phase I randomized, double-blind, placebo-controlled, proof-of-concept study (Q34096856)
Jump to navigation
Jump to search
scientific article
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | LY2439821, a humanized anti-interleukin-17 monoclonal antibody, in the treatment of patients with rheumatoid arthritis: A phase I randomized, double-blind, placebo-controlled, proof-of-concept study |
scientific article |
Statements
1 reference
LY2439821, a humanized anti-interleukin-17 monoclonal antibody, in the treatment of patients with rheumatoid arthritis: A phase I randomized, double-blind, placebo-controlled, proof-of-concept study (English)
1 reference
M C Genovese
1 reference
F Van den Bosch
1 reference
S A Roberson
1 reference
S Bojin
1 reference
I M Biagini
1 reference
Peter Ryan
1 reference
J Sloan-Lancaster
1 reference
1 reference
1 reference
Identifiers
1 reference